Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Hypofractionated schedule, Intensity Modulated Radiotherapy, Conformal radiotherapy
Eligibility Criteria
Inclusion Criteria:
- Patients with diagnosis of prostate cancer
- With age between 18-75 years classified in low
- Intermediate and high-risk group according to their Gleason score
- T stage and initial PSA (iPSA).
- Low risk group included patients with Gleason score <7 / stage T1-T2a, and iPSA <10 ng/mL.
- Intermediate risk included Gleason score < 7, or Stage T1-T2b, or iPSA level of 10-20 ng/mL
- High-risk patients with Gleason score >7, or Stage > T2b, or iPSA >20 ng/mL.
- All patients classified as high risk was submitted to the bone scans.
Exclusion Criteria:
- Patients with metastases
- Prior history of prostatectomy
- Pelvic radiotherapy treatment
- Chemotherapy treatment were excluded of this trial.
Sites / Locations
- Faculty of Medicine of Marilia
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
IMRT- Hypofractionated schedule 70 Gy/25 fx
3DCRT-Hypofractionated schedule 70 Gy/25 fx
The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.